MedTrace Logo

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if salsalate, an Nuclear factor-kappaB (NF-κB) mediated inflammation inhibitor, or carvedilol, an α- and β-blocker, will protect against free fatty acid induced hypertension, insulin resistance, endothelial dysfunction, inflammation and oxidative stress, and autonomic dysfunction in obese normotensive subjects.

Conditions

Interventions

DRUG

Salsalate

Salsalate 750 mg

DRUG

Carvedilol

Carvedilol 3.125 mg

DRUG

Placebo

One tablet

DRUG

Intralipid 20%

24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)

Sponsors & Collaborators

Principal Investigators

  • Guillermo Umpierrez, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02406586 on ClinicalTrials.gov